Therakind receives grant award from Innovate UK
Coveted grant secures UK funding for the development of dry powder nasal antiemetic using DriDose®
London, England – July 2024 – Therakind Limited (“Therakind”), a specialty pharmaceutical company focused on developing and delivering niche medicines for difficult-to-treat patient groups, today announces that it has been awarded a grant from Innovate UK for the formulation development of an antiemetic candidate that will be used with its needle-free, dry powder nasal device technology, DriDose®.
The funding will be used to conduct feasibility studies of an antiemetic, developing bulk dry powder formulations, and characterising their delivery from the DriDose® Multi-dose Cartridge device. This feasibility study will not only provide evidence for nasal antiemetic development but also build a robust data package for DriDose®.
Dr Susan Conroy, CEO of Therakind, said: “Funding by Innovate UK is highly coveted and provides important non-dilutive capital for development of a new antiemetic in our pipeline of candidates to be used in conjunction with DriDose®, our state-of the-art delivery system. Currently, antiemetics are mostly administered orally. Nasal medications can potentially have a faster onset than oral drugs and reduce the risk of oral drug induced regurgitation in patients experiencing nausea and vomiting. We believe that the results of this study will provide further validation of DriDose® as we continue to build out our pipeline of nasal delivered products.”
The DriDose® innovative dry powder nasal delivery device range is designed to incorporate various types of pharmaceutical candidates. The technology includes both single-use and reusable versions, each capable of being modified to accommodate different powder-loading capacities. The reusable device is designed to reduce plastic waste associated with single use devices and injections. The DriDose® device aims to simplify drug delivery and provide an alternative to nasal sprays, nebulizers, tablets, and injections. DriDose® technology has been validated in a clinical trial and tested with a range of molecules in both in vivo and in vitro settings.
For Companies interested in partnering DriDose® with Therakind, please contact us at bd@therakind.com
For more information, please contact:
Therakind Ltd
Dr Susan Conroy, Chief Executive Officer
Tel: ++44 (0) 208 346 603
Email: info@therakind.com
Website: www.therakind.com
About Therakind Limited
Therakind is a specialty pharmaceutical company with a proprietary and partnered pipeline focused on improving medicine adherence through more patient-friendly dosing options. We have a strong track record in the research and development of innovative medicines and drug delivery systems designed specifically to incorporate the pharmacodynamics and pharmacokinetics of difficult-to-treat patient groups. To date, we have developed and obtained marketing authorisations for three products and our intranasal device for the delivery of a dry powder drug formulation, DriDose®, is available for co-development.
About Innovate UK
Innovate UK, part of UK Research and Innovation, is creating a better future by inspiring, involving and investing in businesses developing life-changing innovations.
We provide targeted sectors with expertise, facilities and funding to test, demonstrate and evolve their ideas, driving UK productivity and economic growth. Join our network and communities of innovators to realise the potential of your ideas and accelerate business growth. Innovate UK: inspiring business innovation.
To find out more, please visit www.therakind.com